immuno-oncology

News

Astellas pumps $90m into Sutro immuno-oncology alliance

Astellas has agreed a $1.36 billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates for cancer, focusing on applications in patients who don't respond t

News

Boehringer takes option on masked cytokine specialist Trutin...

Boehringer Ingelheim must like what it has seen in its two-year-old R&D collaboration with Trutino Biosciences to develop cytokine therapies – it has just taken an option to buy the com

News

Roche's Tecentriq extends lead over Keytruda in adjuvant NSC...

While Merck & Co's Keytruda is the undisputed leader of the non-small cell lung cancer (NSCLC) category, there's one category where it lags behind Roche's Tecentriq – treatment of early

News

EU first to clear Roche's lymphoma bispecific mosunetuzumab

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for patients with follicular lymphoma (FL) in the EU.

News

Astellas taps GO's glycoprotein platform with $783.5m deal

Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targ

News